Quintiles has partnered with Population Genetics Technologies (PGT), a U.K.-based company that specializes in large-scale, lower-cost genomic analyses, according to PharmaTimes.

Quintiles’ view of its non-exclusive commercial collaboration with PGT is about bringing “genomic testing into mainstream drug development in order to produce safer, more effective medicines.”

The two companies will seek opportunities to apply large-scale genomic analyses in testing clinical hypotheses and correlating biomarkers of disease prognosis with drug responsiveness.

Quintiles’ global presence and PGT’s technology combined “can bring the benefits of large-scale sequencing and analysis to virtually all biopharmaceutical companies,” says M. King Jolly, senior vice president of Quintiles Innovation.

Other benefits that Jolly notes are improving success rates in clinical trials, reducing the volume of trial enrollment needed to achieve statistical significance and cutting the costs and/or time to bring a product to market.